lenalidomide has been researched along with alpha-synuclein in 2 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (alpha-synuclein) | Trials (alpha-synuclein) | Recent Studies (post-2010) (alpha-synuclein) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 10,821 | 29 | 8,011 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, S; Mante, M; Masliah, E; Rockenstein, E; Valera, E | 1 |
| Adame, A; Desplats, P; Fields, JA; Mante, M; Masliah, E; Rockenstein, E; Spencer, B; Trinh, I; Valera, E | 1 |
2 other study(ies) available for lenalidomide and alpha-synuclein
| Article | Year |
|---|---|
Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Cell Line, Transformed; Cytokines; Disease Models, Animal; Dopamine; Glial Fibrillary Acidic Protein; Immunologic Factors; Lenalidomide; Mental Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Parkinson Disease; RNA, Messenger; Signal Transduction; Thalidomide | 2015 |
Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy.
Topics: alpha-Synuclein; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Gliosis; Humans; Immunotherapy; Lenalidomide; Mice, Transgenic; Multiple System Atrophy; Proto-Oncogene Proteins c-akt; Signal Transduction; Single-Chain Antibodies; Thalidomide; Tumor Necrosis Factor-alpha | 2017 |